Surgical recovery and dry eye growth drive margins higher
- Q2 2026 showed broad momentum with operating margin expanding 260 basis points year over year to 17.6 percent.
- The Surgical segment bounced back with 16 percent constant currency growth, led by a massive 175 percent jump in premium IOLs.
- The dry eye drug pair of MIEBO and XIIDRA continued to perform well, with MIEBO revenue growing 44 percent year over year.
- Management raised full year 2026 adjusted EBITDA guidance again, now targeting between $1.025 billion and $1.075 billion.
- Investors are now watching key clinical data readouts in the second half of 2026, including the ELIOS implant-free surgical system.
Surgical rebuild fuels the leverage case
Bausch + Lomb answered its biggest question in Q2 2026. After a soft start to the year, the Surgical segment recovered with 16 percent constant currency growth. That recovery combined with strong dry eye drug sales to drive significant operating leverage. Operating margin expanded 260 basis points year over year to 17.6 percent.
The bull case focuses on this exact dynamic. The company is successfully executing its strategy to turn revenue growth into even faster profit growth. The product mix is shifting toward higher margin items, especially premium intraocular lenses and the dry eye drug MIEBO. Because of this success, management raised full year EBITDA guidance for the second straight quarter.
The bear case shifts away from basic sales execution and toward pipeline risk and the broader economy. To sustain long term growth, the company must deliver positive clinical data on upcoming projects. That includes the ELIOS surgical system and a new dual-action dry eye treatment. The consumer health business could also see slower sales if higher gas prices and inflation pressure household budgets.
The setup looks stronger than it did three months ago. The company proved it can fix the Surgical division while keeping pharmaceutical sales growing. Now the focus turns to the second half of 2026, where pipeline approvals will decide if the momentum can continue into 2027.
Three ways to sell eye care
Bausch + Lomb is a complete eye health company. It makes and sells about 400 products across around 100 countries. The product range runs from daily contact lenses and over-the-counter drops to prescription eye drugs and surgical equipment.
The model has three parts. Vision Care brings scale through contact lenses, lens care, Lumify, Blink, and PreserVision. Pharmaceuticals can grow faster when branded drugs like MIEBO and XIIDRA gain share. Surgical sells devices and consumables used in cataract and retinal procedures.
Management relies on a fourth operating pillar called financial excellence. In plain English, this means strict cost control, better sales execution, and higher profit margins. The strategy is working. The mix shift toward premium surgical lenses and high margin dry eye drugs is making the overall business significantly more profitable.
The model can break if drugs lose patent protection, rebates rise faster than sales, or new clinical trials fail. The parent company, Bausch Health, also still holds a majority stake. This ownership structure means full separation or sale timing remains part of the story.
The portfolio that matters most
MIEBO and XIIDRA
These are the core dry eye prescription drugs. In Q2 2026, MIEBO revenue rose 44 percent year over year to $91 million.
Contact lenses and lens care
This includes Biotrue ONEday, INFUSE, ULTRA, Biotrue, and Renu. It gives Vision Care a large recurring base because people keep buying lenses and solutions.
Lumify, Blink, and PreserVision
These are consumer eye care products sold without a prescription. A multi-year study has also begun for a myopia control contact lens.
enVista and premium IOLs
IOLs are artificial lenses used in cataract surgery. Premium IOLs grew 175 percent in Q2 2026, pushing premium mix to 13 percent of surgical revenue.
ELIOS system
An implant-free excimer laser system for surgery. The company expects FDA approval and a subsequent launch in the second half of 2026.
Vyzulta, Lotemax, and other prescription drugs
These drugs help round out the Pharmaceuticals segment across glaucoma, inflammation, and other eye conditions. The risk is that older products can face generic competition.
Q2 mix shows Vision Care leads
Segment mix uses Q2 2026 revenue: Vision Care $784 million, Pharmaceuticals $354 million, and Surgical $256 million. The total was approximately $1.394 billion.
What could go wrong
Pipeline clinical failures
High impact · Medium oddsThe company needs new products to keep growing. Investors are waiting for top line data on a phase two dry eye study by the end of Q3 2026, and the ELIOS surgical launch in late 2026. A failed trial or delayed launch would hurt future growth estimates.
Consumer health spending slowdown
Medium impact · Medium oddsThe Vision Care segment relies on consumer spending for products like contact lenses and vitamins. Management warned that macroeconomic pressures, such as high gas prices, could cause modest volatility in consumption trends.
Rebates eat the drug upside
Medium impact · Medium oddsGross-to-net pressure means discounts, rebates, and fees reduce reported drug sales. As MIEBO and XIIDRA grow, the total cost of rebates also grows. If rebates keep rising, strong patient demand may not fully show up in revenue or profit.
Patent and generic pressure
High impact · Medium oddsThe company faces generic competition and loss of exclusivity risk across its drug portfolio. It also has patent infringement proceedings tied to major products such as Lumify and PreserVision. A bad ruling could cut sales or force higher legal spend.
Bausch Health overhang remains
Medium impact · Medium oddsBausch Health still owns a majority stake in Bausch + Lomb. That creates uncertainty around the timing and form of a full separation, and it may affect any potential sale of the company. Investors may apply a discount until ownership is clearer.
In one breath
What does Bausch + Lomb actually sell?
It sells eye care products across three groups: Vision Care, Pharmaceuticals, and Surgical. That includes contact lenses, lens solutions, eye drops, prescription drugs, and devices used in cataract and retinal surgery.
Why are MIEBO and XIIDRA so important?
They are the main growth drivers in dry eye, a large eye care market. In Q2 2026, MIEBO revenue grew 44 percent year over year, which helped prove the margin expansion case.
Is the Surgical business struggling?
No, it recovered strongly in Q2 2026. After a soft start to the year, the segment grew 16 percent in constant currency, led by massive growth in premium surgical lenses.
Is BLCO fully separated from Bausch Health?
No. Bausch Health still holds a majority stake, so full separation remains an overhang. That ownership structure can affect investor sentiment and any possible sale process.
